Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs
Oncomatryx will attend BIOEUROPE. November 7-9. Cologne. FOCUS. November 9-12. Cyprus. If you are also attending any of these events and you would like to meet us please fill
Oncomatryx at the “Cancer Metabolism and the Tumour Microenvironment Conference”. 9-12, November. Paphos, Cyprus. Myriam Fabre, PhD. (Oncomatryx R&D Director) will attend the conference as speaker: TARGETING TUMOR MICROENVIRONMENT TO
Poster presentation at the 2nd ASPIC International Congress. 28-29 April, 2016. Porto. Portugal. We are pleased to inform you that Enrique De Alava team from Hospital Virgen del Rocío, Sevilla, Spain,
Published by La Vanguardia 2015-12-15. Oncomatryx expands capital to complete the preclinical phase of drugs against tumor stroma The Basque company Oncomatryx has completed a round of capital increase of
War on cancer stroma: a novel pathway to treat pancreatic cancer By Laureano Simon, CEO at Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients
6th World ADC Summit. 8th-10th February 2016. Berlin (Germany). ONCOMATRYX will be attending World ADC Berlin. Poster Presentation: “OMTX705, a powerful stroma-targeting ADC to treat invasive tumors” by Myriam Fabre, PhD. If you
Tumor microenvironment: A cancer key player to be fired Novel precision drugs that target the tumor microenvironment are entering the battlefield against cancer. Recent advances in the prevention and treatment
